Loxo Oncology (LOXO) Posts Wider Q3 Loss

Loxo Oncology (NASDAQ: LOXO) reported Q3 EPS of ($2.45), $1.03 worse than the analyst estimate of ($1.42).

As of September 30, 2017, Loxo Oncology had aggregate cash, cash equivalents and investments of $405.3 million, compared to $141.8 million as of December 31, 2016.

“In recent months, we have announced meaningful progress across our TRK and RET programs,” said Josh Bilenker, M.D., chief executive officer of Loxo Oncology. “For larotrectinib, an independent review committee has corroborated the striking response rate reported at ASCO. These data will anchor global regulatory submissions, including a U.S. submission which is on track for late 2017 or early 2018. For RET, study investigators provided a first look at LOXO-292’s potential at the recent World Lung meeting in Japan. The LOXO-292 Phase 1 trial continues to enroll well, and we look forward to providing a study update in 2018.”

For earnings history and earnings-related data on Loxo Oncology (LOXO) click here.

You May Also Be Interested In

• Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
• Power Integrations (POWI) Tops Q3 EPS by 5c; Offers Guidance
• PureCycle Technologies, Inc. (PCT) Tops Q3 EPS by 25c